A pilot study of netilmicin pharmacokinetics during continuous venovenous hemodiafiltration

Journal of Clinical Pharmacology

Volumn 45, Issue 4, 2005, Pages 477-481

  Syka, Maria ^a   Markantonis, Sophia L ^a   Mathas, Christos ^b   Maggina, Nina ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b Intensive Care Unit   (Greece)

Author keywords

Continuous venovenous hemodiafiltration (CVVHD); Netilmicin; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; NETILMICIN;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; CRITICAL ILLNESS; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GRAM NEGATIVE INFECTION; HEART FAILURE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER FAILURE; LUNG EDEMA; MALE; PILOT STUDY; SINGLE DRUG DOSE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEMOFILTRATION; HUMANS; MALE; NETILMICIN; PILOT PROJECTS;

EID: 16844381058     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004273949     Document Type: Article

References (14)

1. Ristuccia AM, Cunha BA. The aminoglycosides. Med Clin North Am. 1982;66:303-312.
2. Campoli-Richards DM, Chaplin S, Sayce RH, Goa KL. Netilmicin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1989;38:703-756.
3. Silvester W. Outcome studies of continuous renal replacement therapy in the intensive care unit. Kidney Int. 1998;66(suppl 66):S138-S141.
4. Breilh D, Allaouchiche B, Jaumain H, Bouletrau P, Chassard D, Malbec I, et al. Pharmacokinetics of isepamicin during continuous veno-venous hemodiafiltration. Antimicrob Agents Chemother. 1999;43:2409-2411.
5. Ernest D, Cutler DJ. Gentamicin clearance during continuous arteriovenous hemodiafiltration. Crit Care Med. 1992;20:586-589.
6. Robert R, Rochard E, Malin F, Bouquet S. Amikacin pharmacokinetics during continuous veno-venous hemodiafiltration. Crit Care Med. 1991;19:588-589.
7. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93-99.
8. Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm. 1986;5:319-324.
9. Gowan AM, Reeves D. Serum aminoglycoside concentrations: the case for routine monitoring. J Antimicrob Chemother. 1994;34:829-837.
10. Lehman ME, Kolb KW. Gentamicin elimination in a patient undergoing continuous ultrafiltration. Clin Pharm. 1985;4:327-330.
11. Zarowitz BJ, Anandan JV, Dumler F, Jayashankar J, Levin N. Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients. J Clin Pharmacol. 1986;26:686-689.
12. Armstrong DK, Hidalgo HA, Eldadah M. Vancomycin and tobramycin clearance in an infant during continuous hemofiltration. Ann Pharmacother. 1993;27:224-227.
13. Armendariz Z, Chelluri L, Ptachcinski R. Pharmacokinetics of amikacin during continuous veno-venous hemofiltration. Crit Care Med. 1990;18:675-676.
14. Winter ME. Basic Clinical Pharmacokinetics. 3rd ed. Vancouver, WA: Applied Therapeutics, Inc; 1994.